Inclusion and exclusion criteria
All eligible Studies were selected with the following inclusion
criteria: (1) clinical trials and
observational studies, (2) studies explored the association betweenUGT1A1*6 and/or UGT1A1*28 or ABCC2 and
irinotecan-induced toxicities, (3) studies included patients suffering
from neutropenia hematological toxicity and diarrhea (grade III–IV),
(4) studies comparing both homozygous and heterozygous versus wild type
and (5) studies were published in English.
Exclusion criteria were the following: (1) non-English papers, (2)
reviews and case-reports, (3) animal experiments, (4) studies without
results about the toxicity of neutropenia or diarrhea, (5) studies with
undefined genotypes and (6) studies simply focusing on the allele
frequency of either UGT1A1*6, *28 or ABCC2 without any
correlation with toxicity.